5 Harmful Foods To Avoid For Better Health & Weight Loss

When people decide it's time to eat healthier to lose weight or manage a health condition, they ask the same question: What should I eat? Answers typically come in the form of which diet to follow: keto, paleo, plant-based, Mediterranean or something else. But here's a better question and one that may lead to bigger, longer-lasting change: What harmful foods should I not eat?
We've lost sight of a deceptively simple truth. Most health improvements from dietary change don't come from adding so-called superfoods. They come from removing the foods that are actively hurting our health.
There may be individual reasons to follow a specific diet — food sensitivities, religious or cultural preferences or a physician's guidance. But for most, focusing on what not to eat may be the most impactful and sustainable diet of all.
The modern American diet is dominated by ultra-processed, calorie-dense nutrient-poor foods. More than 60% of the average American's calories come from ultra-processed products. Think packaged snacks, sugary drinks, frozen meals, fast food and refined carbohydrates.
These foods are actively harmful to health. Study after study links diets high in ultra-processed foods to obesity, heart disease, type 2 diabetes, cancer, and early death. In one randomized trial, just two weeks on an ultra-processed diet led to significant weight gain and increases in hunger hormones — even when calories and macronutrients (e.g. proteins, carbohydrates and fats) were matched.
Ultra-processed foods don't just make us sick, they're designed to override satiety signals, encouraging us to eat way more than we need.
People often begin a diet by trying to add in healthier foods: a protein shake, oatmeal with blueberries or a salad at lunch. That's great — unless it's followed by a soda and a bag of chips later.
Here's what works better: subtraction first.
Cutting out refined sugar, white flour, ultra-processed snacks and heavily refined seed oils creates space for healthier choices to naturally take their place. People often report feeling better, craving less and even losing weight without counting calories. Just by cutting out the junk food.
Think of it as nutritional minimalism: instead of obsessing over what to eat, ask what you can do without. This gives you flexibility. You can eat Mediterranean on Monday, Asian on Tuesday and plant-based on Wednesday. As long as the foods are whole and minimally processed, you're moving in the right direction.
Yes, calories matter. But where they come from matters more.
Two-hundred calories from salmon and broccoli is not the same as 200 calories from soda and cookies. The former fuels satiety, muscle repair and leads to stable blood sugar levels. The latter triggers glucose spikes, inflammation and rebound hunger.
The real issue isn't just overeating — it's over-consuming 'bad' calories. When you remove the foods that spike insulin, disrupt hormones and hijack appetite regulation, you naturally eat fewer total calories because your body self-regulates more effectively.
No matter the diet philosophy, there's surprising consensus among experts about what to avoid. Here are the top offenders:
Removing these — even partially — can improve energy, sleep, mood and hunger. Unlike restrictive diets, this lets you eat in any style that works for you — as long as you're cutting out the worst offenders.
Most diets fail not because people don't know what to eat, but because they're too complicated or rigid. A subtraction-first approach is simpler and more sustainable.
You don't have to adopt a 'perfect' diet overnight. Start with a single rule: no sugary drinks. Or avoid any product with more than five ingredients. These changes add up —gradually shifting habits often without requiring calorie tracking, apps or special meal plans.
This is also empowering. You're not relying on a meal delivery service or overpriced powders. You're simply removing low value and harmful foods.
There's a hidden psychological advantage too. When you focus on what not to eat, you reduce decision fatigue. Saying 'I don't drink soda' or 'I don't eat fast food' provides a mental shortcut. These are called identity-based habits — and research shows they're more durable than external rules, according to Atomic Habits author James Clear.
Yet taken to an extreme, this mindset can be problematic. It's not about cutting everything. It's about avoiding the foods most linked to fatigue, cravings and disease—not creating anxieties.
Importantly, it's not about perfection. A diet that's 90% clean is dramatically better than one that's 50%. Even halving your (or your kids') intake of ultra-processed food can yield meaningful results.
This 'cut the junk' strategy is increasingly backed by science. A 2024 BMJ study linked high ultra-processed food intake to higher risk of death from all causes.
Yet many diet plans still push complex and unsustainable approaches: 'Eat these 12 superfoods" or 'Only eat high-fat, high-protein, low carbohydrate foods.'
Sometimes the best advice is the simples: Eat real food; cut out the harmful foods; and let your body do the rest.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

25 minutes ago

• Yahoo

GE HealthCare drives innovation in theranostics with latest technological advances

GE HealthCare is helping advance clinical and operational excellence in theranostics and molecular imaging through a comprehensive portfolio of AI-powered imaging technologies, radiopharmaceuticals, cyclotrons, chemistry systems, and workflow-optimizing software—designed to support personalized, data-driven care across the entire patient journey. At #SNMMI25, the company is proud to introduce LesionID™ Pro with automated zero-click pre-processing,i which aims to help physicians minimize manual segmentation required to access patient-specific insights that can play a key role in delivering precision care with confidence. CHICAGO, June 21, 2025--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processingi – an AI-powered innovation to help aid physician decision making and therapy response monitoring. With cancer accounting for over 10 million deaths globally each year,ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. "Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice," shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. "With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives." Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing,i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. "At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics," shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. "We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes." Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni,iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40%iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT.v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilitiesvi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systemsvii – with the ability to reduce the dose up to 82%,viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. "Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care," says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing.v Based on orders data of GE HealthCare PET/CT systems since Compared to NM/CT 870 As compared to NM/CT 870 DR with Optima 540 a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability).viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method. View source version on Contacts GE HealthCare Media Contact: Margaret SteinhafelM +1 608 381 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Medscape

30 minutes ago

• Medscape

Stem Cell-Derived Islets Still Producing Insulin at 1 Year

CHICAGO — Ten people with type 1 diabetes, who had recurrent severe hypoglycemia and hypoglycemic unawareness, have remained insulin-independent for over a year following allogeneic stem cell-derived islet-cell therapy with immunosuppression, according to new phase 1/2 data from the multicenter FORWARD study sponsored by Vertex Pharmaceuticals. The insulin-producing therapy VX-880, now named zimislecel, is delivered by infusion into the hepatic portal vein. A steroid-free immunosuppressive regimen is used, involving induction with antithymocyte globulin followed by maintenance with tacrolimus plus sirolimus. "It's really exciting to have a consistent, scalable source of insulin-producing tissue," study investigator Michael R. Rickels, MD, of the University of Pennsylvania School of Medicine, Philadelphia, told Medscape Medical News . Even with the need for immunosuppression, there are many patients who could benefit from cell therapy, including those experiencing severe hypoglycemia or having challenges with glycemic control, or those already immunosuppressed for an organ transplant, he said. "Having a product with reproducible efficacy and an established safety record will be important in testing new immunomodulatory approaches, and ultimately other approaches for immune evasion, whether that's through engineering or gene-editing types of approaches in the future," added Rickels. The findings were presented on June 20 here at the American Diabetes Association (ADA) 85th Scientific Sessions and simultaneously published in the New England Journal of Medicine . Asked for comment, Jeffrey R. Millman, PhD, a professor of medicine and biomedical engineering at Washington University School of Medicine, St. Louis, Missouri, who helped develop the technique for deriving islets from stem cells, told Medscape Medical News: "It's what we hoped, but seeing it actually happen is just amazing. There's no stem cell-based therapy has come close to what they've been able to accomplish." But, Millman added, "It's still only going to be for a small portion [of people] with type 1 diabetes, which is why we need to have things like encapsulation or genetic engineering to avoid the immunosuppression part, to make it a therapy that's much more applicable to most or all people living with type 1 diabetes." 1-Year Data The new data extend the findings reported at last year's ADA meeting and continue to demonstrate the feasibility of the therapy for people with type 1 diabetes in whom the risks of immunosuppression outweigh the benefits. The 14 participants (5 men, 9 women) included in the analysis who completed 1 year of follow-up had a mean age of 43.6 years and a mean type 1 diabetes duration of 22.8 years. All had undetectable C-peptide at baseline, a mean A1c of 7.8%, and a mean total daily insulin dose of 39.3 units. All used continuous glucose monitors, 9 used insulin pumps, and 6 used automated insulin delivery systems. Despite the technology, study participants had had an average of 2.7 severe hypoglycemic episodes in the year prior to screening. All participants had engraftment and infusion, as detected by the appearance of C-peptide. Two patients received a half dose of zimislecel, and 12 received a full dose (0.8 × 109 cells) in a single infusion. At 1 year, none of the 14 patients had experienced severe hypoglycemia. All 12 who received the full dose were free of severe hypoglycemic events and had an A1c level below 7%. They also spent more than 70% of the time in the target glucose range (70-180 mg/dL), and 10 patients were insulin independent at 365 days. There were 14 adverse events, including diarrhea, headache, and nausea. Most were mild to moderate and attributed to the immune suppression. Neutropenia occurred in six participants. Two patients died, one from cryptococcal meningitis attributed to the immune suppression and one from severe dementia with agitation owing to the progression of preexisting neurocognitive impairment. The deaths resulted in a temporary pause of the research in early 2024. Overcoming the Need for Immune Suppression Millman said he is not optimistic about the potential of islet encapsulation techniques — several of which were discussed at the ADA meeting — of overcoming the need for immune suppression. "Encapsulation is promising in the sense that it is relatively simple in concept and execution, but historically it's been very challenging," he said. "The problem is that you need a certain amount of islets creating a certain amount of insulin to control blood sugars in an adult human. These cells have certain metabolic needs for glucose for the oxygen that they breathe, and if you are encapsulating them, these cells are not able to rely on blood vessels to provide the nutrients and oxygen that they need," Millman explained. He added, "There can potentially be more advanced ways of doing that that can overcome those barriers, but so far there hasn't been conclusive proof that that can be done in a way that translates to patients." Indeed, in March 2025 Vertex discontinued a phase 1/2 trial of an encapsulated islet product VX-264 because of lack of efficacy. Instead, Millman and others in the field are more optimistic about hypoimmune gene editing of the islets to avoid the necessity for immunosuppressant drugs. "There's been a lot of interesting scientific work coming out from both companies and academic labs with different ways of engineering cells to avoid immune destruction," he noted. Although this research is still in its early stages, Millman pointed to upcoming programs, such as one announced by Sana Biotechnology, for which a 6-month update will be presented here at the ADA meeting on Monday. "I'm hoping that we can learn from that, similar to what we just learned here today from Vertex Pharmaceuticals, about the challenges and the promises of genetic engineering to avoid the need for immunosuppression." Zimislecel will now be studied in a phase 3 trial, with a planned enrollment of 50 patients, to be completed by the end of summer 2025. Rickels has reported being a consultant for Vertex Pharmaceuticals and Sernova, receiving research support from Dompé and Tandem Diabetes Care, and being a consultant for Novo Nordisk. Millman has reported holding stock in and receiving research support from Sana Biotechnology.

Yahoo

42 minutes ago

• Yahoo

Sword Health Now Valued At $4 Billion, Announces Expansion Into Mental Health Services

Sword Health announced Tuesday that it had raised $40 million in a recent funding round, giving it a $4 billion valuation. Founded in 2015, the healthcare startup has focused on helping people manage chronic pain at home. Using AI tools, the platform connects users with expert clinicians who then provide patients with tools for digital physical therapy, pelvic health, and overall mobility health. However, the company says this new round of funding will largely go towards developing a mental health arm of its program called Mind. Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can "Today, nearly 1 billion people worldwide live with a mental health condition. Yet care remains fragmented, reactive, and inaccessible," Sword said in the announcement. "Mind redefines mental health care delivery with a proactive, 24/7 model that integrates cutting-edge AI with licensed, Ph.D-level mental health specialists. Together, they provide seamless, contextual, and responsive support any time people need it, not just when they have an appointment." Sword CEO Virgílio Bento told CNBC, "[Mind] really a breakthrough in terms of how we address mental health, and this is only possible because we have AI." Users will be equipped with a wearable device called an M-band, which will measure their environmental and physiological signals so that experts can reach out proactively as needed. The program will also offer access to services like traditional talk therapy. Bento told CNBC that a human is "always involved" in patients care in each of its programs, and that AI is not making any clinical decisions. Trending: Maximize saving for your retirement and cut down on taxes: . For example, if a Sword patient has an anxiety attack, AI will identify it through the wearable and bring it to the attention of a clinician, who can then provide an appropriate care plan. "You have an anxiety issue today, and the way you're going to manage is to talk about it one week from now? That just doesn't work," Bento told CNBC. "Mental health should be always on, where you have a problem now, and you can have immediate help in the moment." According to Bento, Sword Mind already has a waiting list, and is being tested by some of its partners who appreciate it's "personalized approach and convenience." "We believe that it is really the future of how mental health is going to be delivered in the future, by us and by other companies," he told CNBC. "AI plays a very important role, but the use of AI — and I think this is very important — needs to be used in a very smart way." The rest of the cash raised in the funding round, which was led by General Catalyst, will go towards acquisitions, global expansion, and AI development, Sword Health says. Read Next: Here's what Americans think you need to be considered Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article Sword Health Now Valued At $4 Billion, Announces Expansion Into Mental Health Services originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data